Kyle Gano to lead Neurocrine in post-Kevin Gorman era

29 May 2024

After more than 30 years with neuroscience-focused biopharma Neurocrine Biosciences (Nasdaq: NBIX), founder and chief executive Kevin Gorman is to retire in October - albeit staying on as a board member.

Kyle Gano, currently Neurocrine's chief business development and strategy officer, will succeed him in the CEO role and will also join the board.

Dr Gorman founded Neurocrine in 1992 and held numerous positions across the San Diego-based company, including chief operating officer, chief business officer, and senior vice president of business development, before being appointed CEO in 2008.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK